Efficacy, Self, Safety Issues
Conditions
Keywords
osteosarcoma, ewing sarcoma, chondrosarcoma, PI3KA mutation, PTEN loss, TQB3525
Brief summary
The PI3K, protein kinase B (AKT), and mTOR signaling network promotes cell growth, survival, metabolism, and motility, but becomes a critical oncogenic driver under aberrant conditions that control the tumor microenvironment and angiogenesis. The PI3K-AKT-mTOR axis is the most frequently deregulated signaling pathway in primary osteosarcoma and other bone tumors. PI3Ka has high rates of 25-50% activating mutations associated with tumor formation in osteosarcoma. Other causes of pathway hyperactivation include loss of function of the tumor suppressor PTEN, gain-of-function mutations in AKT and PDK1, or upregulation of receptor tyrosine kinases. TQB3525 is an orally bioavailable, potent, dual catalytic site inhibitor of PI3Ka and PI3Kd. Tumor growth inhibition has been demonstrated in multiple xenograft osteosarcoma models with PI3K-mutant, PTEN-null cell lines. The investigators try to investigate TQB3525 in primary osteosarcoma and other bone tumors for its safety, tolerability, dose-limiting toxicities (DLT), MTD and antitumor efficacy.
Interventions
DRUGTQB3525
TQB3525 is an orally bioavailable, potent, class I kinase inhibitors of PI3Ka and PI3Kd.
Sponsors
Peking University People's Hospital
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Intervention model description
TQB3525 orally taken
Eligibility
Sex/Gender
ALL
Age
12 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* progression upon first-line chemotherapy; * with target lesions according to RECIST 1.1; * geno-profiling with PI3KA mutations or PTEN loss; * ECOG PS status 0 or 1 with a life expectancy \>3 months; * adequate renal, hepatic, and hematopoietic function;
Exclusion criteria
* been previously exposed to other TKIs; * had central nervous system metastasis; * had other kinds of malignant tumors at the same time; * had cardiac insufficiency or arrhythmia; * had uncontrolled complications such as diabetes mellitus, coagulation disorders, urine protein ≥ ++, and so on; * had pleural or peritoneal effusion that needed to be handled by surgical treatment; * had other infections or wounds; * pregnant or breastfeeding.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| toxicity profiles | 6 months | according to CTCAE 5.0 |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| progression free survival | 6 months | from starting treatment to progression/death |
| overall survival | 2 years | from starting treatment to death |
Other
| Measure | Time frame | Description |
|---|---|---|
| fasting triglyceride | 6 months | dynamic changes from Peripheral Blood |
| fasting lipoprotein | 6 months | dynamic changes from Peripheral Blood |
| fasting insulin | 6 months | dynamic changes from Peripheral Blood |
Countries
China
Outcome results
None listed